Published in J Biol Chem on September 11, 2008
The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res (2009) 3.40
Molecular pathology of age-related macular degeneration. Prog Retin Eye Res (2008) 3.35
Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol (2010) 1.68
Atypical hemolytic uremic syndrome. Semin Nephrol (2013) 1.56
A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest Ophthalmol Vis Sci (2009) 1.54
Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B. Proc Natl Acad Sci U S A (2009) 1.36
Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Bruch's membrane in human retina. J Biol Chem (2010) 1.36
CCL2/CCR2 and CX3CL1/CX3CR1 chemokine axes and their possible involvement in age-related macular degeneration. J Neuroinflammation (2010) 1.18
Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J Biol Chem (2009) 1.15
Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol (2013) 1.14
Mechanism of inflammation in age-related macular degeneration. Mediators Inflamm (2012) 1.14
Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype. Int J Epidemiol (2012) 1.12
Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions. J Immunol (2013) 1.06
Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: effects of phosphoethanolamine. Clin Chim Acta (2009) 1.05
Factor h: a complement regulator in health and disease, and a mediator of cellular interactions. Biomolecules (2012) 0.99
Identification of acidic pH-dependent ligands of pentameric C-reactive protein. J Biol Chem (2010) 0.96
Identification of factor H-like protein 1 as the predominant complement regulator in Bruch's membrane: implications for age-related macular degeneration. J Immunol (2014) 0.91
The role of CRP and inflammation in the pathogenesis of age-related macular degeneration. Biochem Med (Zagreb) (2012) 0.85
Probing the phosphocholine-binding site of human C-reactive protein by site-directed mutagenesis. J Biol Chem (1992) 0.85
C-reactive protein and coronary heart disease: all said--is not it? Mediators Inflamm (2014) 0.83
The interaction of canine plasminogen with Streptococcus pyogenes enolase: they bind to one another but what is the nature of the structures involved? PLoS One (2011) 0.82
The phosphocholine-binding pocket on C-reactive protein is necessary for initial protection of mice against pneumococcal infection. J Biol Chem (2012) 0.81
Factor H-related protein 5 interacts with pentraxin 3 and the extracellular matrix and modulates complement activation. J Immunol (2015) 0.80
Protection of host cells by complement regulators. Immunol Rev (2016) 0.79
C-reactive protein protects mice against pneumococcal infection via both phosphocholine-dependent and phosphocholine-independent mechanisms. Infect Immun (2015) 0.79
Complement factor H binding of monomeric C-reactive protein downregulates proinflammatory activity and is impaired with at risk polymorphic CFH variants. Sci Rep (2016) 0.77
Functional transformation of C-reactive protein by hydrogen peroxide. J Biol Chem (2017) 0.75
Complement factor H polymorphism in age-related macular degeneration. Science (2005) 31.10
Complement factor H variant increases the risk of age-related macular degeneration. Science (2005) 17.95
Complement factor H polymorphism and age-related macular degeneration. Science (2005) 17.79
A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A (2005) 13.44
Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res (2001) 4.38
The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol (2004) 4.16
Targeting C-reactive protein for the treatment of cardiovascular disease. Nature (2006) 4.07
Sedimentation equilibrium analysis of protein interactions with global implicit mass conservation constraints and systematic noise decomposition. Anal Biochem (2004) 3.71
Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest (1993) 2.92
The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure (1999) 2.64
The central role of the alternative complement pathway in human disease. J Immunol (2006) 2.53
Factor H family proteins: on complement, microbes and human diseases. Biochem Soc Trans (2002) 2.23
Structural basis for complement factor H linked age-related macular degeneration. J Exp Med (2007) 2.02
Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol (2007) 2.00
Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol (2007) 1.94
Three dimensional structure of human C-reactive protein. Nat Struct Biol (1996) 1.87
His-384 allotypic variant of factor H associated with age-related macular degeneration has different heparin binding properties from the non-disease-associated form. J Biol Chem (2006) 1.79
Regulation of complement activation by C-reactive protein. Immunopharmacology (1999) 1.78
A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein. Eur J Immunol (2003) 1.77
Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand J Immunol (2006) 1.70
Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J Immunol (1974) 1.68
Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology (1982) 1.67
Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc Natl Acad Sci U S A (2006) 1.63
The factor H variant associated with age-related macular degeneration (His-384) and the non-disease-associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells. J Biol Chem (2007) 1.51
Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol (1999) 1.42
Structure shows that a glycosaminoglycan and protein recognition site in factor H is perturbed by age-related macular degeneration-linked single nucleotide polymorphism. J Biol Chem (2007) 1.36
Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55). J Biol Chem (2004) 1.35
Expression, detection and assay of a neoantigen (Neo-CRP) associated with a free, human C-reactive protein subunit. Mol Immunol (1987) 1.27
Extensive deposits of complement C3d and C5b-9 in the choriocapillaris of eyes of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci (2002) 1.17
Structural and functional comparison of native pentameric, denatured monomeric and biotinylated C-reactive protein. Immunology (2006) 1.16
Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities. Mol Neurobiol (2002) 1.14
Functional and structural implications of the complement factor H Y402H polymorphism associated with age-related macular degeneration. Invest Ophthalmol Vis Sci (2008) 1.12
Elucidation of a protease-sensitive site involved in the binding of calcium to C-reactive protein. Biochemistry (1989) 1.07
Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies. J Clin Lab Immunol (1992) 1.07
C-reactive protein inhibits pneumococcal activation of the alternative pathway by increasing the interaction between factor H and C3b. J Immunol (1984) 1.06
Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium. Mol Immunol (1983) 1.05
Separation of active and inactive forms of the third component of human complement, C3, by fast protein liquid chromatography (FPLC). J Immunol Methods (1989) 1.04
Biochemical analysis of a common human polymorphism associated with age-related macular degeneration. Biochemistry (2007) 1.03
Identification and partial characterization of multiple native and neoantigenic epitopes of human C-reactive protein by using monoclonal antibodies. J Immunol (1989) 1.02
Studies on the interactions between C-reactive protein and complement proteins. Immunology (2007) 1.01
Expression, purification, cocrystallization and preliminary crystallographic analysis of sucrose octasulfate/human complement regulator factor H SCRs 6-8. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.89
Conduct unbecoming: C-reactive protein interactions with a broad range of protein molecules. J Heart Lung Transplant (2007) 0.82
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med (2004) 15.30
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet (2009) 11.81
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med (2002) 4.47
Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2006) 3.80
Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet (2010) 3.74
Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ (2011) 3.65
IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain (2008) 2.91
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol (2003) 2.74
C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol (2005) 2.64
Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med (2007) 2.55
Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res (2013) 2.26
Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest (2010) 2.18
Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. Clin Chem (2003) 2.15
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood (2002) 1.87
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med (2015) 1.84
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81
C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proc Natl Acad Sci U S A (2012) 1.73
Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol (2012) 1.67
Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc Natl Acad Sci U S A (2013) 1.63
Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A (2005) 1.62
Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol (2003) 1.61
Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci U S A (2011) 1.60
Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation (2004) 1.59
Variant-specific quantification of factor H in plasma identifies null alleles associated with atypical hemolytic uremic syndrome. Kidney Int (2010) 1.56
CD59a deficiency exacerbates accelerated nephrotoxic nephritis in mice. J Am Soc Nephrol (2003) 1.54
Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFNgamma-dependent iNOS expression in the vasculature of healthy mice. Blood (2008) 1.53
The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Hum Mol Genet (2009) 1.52
C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest (2013) 1.52
Tetracycline protects against dermonecrosis induced by Loxosceles spider venom. J Invest Dermatol (2007) 1.50
Retracted Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma. Cancer Res (2008) 1.49
CD59a is the primary regulator of membrane attack complex assembly in the mouse. J Immunol (2004) 1.45
A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood (2012) 1.45
The human complement fragment receptor, C5L2, is a recycling decoy receptor. Mol Immunol (2008) 1.45
The solution structure of human beta2-microglobulin reveals the prodromes of its amyloid transition. Protein Sci (2002) 1.44
Normal circulating serum amyloid P component concentration in systemic sclerosis. Arthritis Rheum (2007) 1.42
Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. Eur J Immunol (2003) 1.40
Letter in response to Bisoendial et al: "activation of inflammation and coagulation after infusion of C-reactive protein in humans". Circ Res (2005) 1.39
Complement: central to innate immunity and bridging to adaptive responses. Immunol Lett (2004) 1.36
Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B. Proc Natl Acad Sci U S A (2009) 1.36
Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Bruch's membrane in human retina. J Biol Chem (2010) 1.36
Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55). J Biol Chem (2004) 1.35
The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. J Cell Sci (2013) 1.33
Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation (2005) 1.33
Measurement of factor H variants in plasma using variant-specific monoclonal antibodies: application to assessing risk of age-related macular degeneration. Invest Ophthalmol Vis Sci (2008) 1.32
The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2008) 1.31
CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration. J Immunol (2007) 1.31
Dense deposit disease. Mol Immunol (2011) 1.31
Holding T cells in check--a new role for complement regulators? Trends Immunol (2006) 1.30
Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. J Immunol (2009) 1.30
Beyond lysis: how complement influences cell fate. Clin Sci (Lond) (2003) 1.30
The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol (2002) 1.28
Human plasma fibrinogen is synthesized in the liver. Blood (2006) 1.27
Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med (2012) 1.26
Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int (2010) 1.25
Complement therapeutics; history and current progress. Mol Immunol (2003) 1.25
Production of granulocyte colony-stimulating factor in the nonspecific acute phase response enhances host resistance to bacterial infection. J Immunol (2002) 1.25
Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. Atherosclerosis (2007) 1.24
Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. J Clin Invest (2011) 1.24
Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood (2005) 1.22
In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata. J Biol Chem (2007) 1.22
Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J Cereb Blood Flow Metab (2004) 1.21
Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1β release. J Immunol (2013) 1.20
Complement dysregulation and disease: from genes and proteins to diagnostics and drugs. Immunobiology (2012) 1.19
Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the MONICA Augsburg studies, 1984 and 1987. Am J Epidemiol (2003) 1.18
Structural and functional comparison of native pentameric, denatured monomeric and biotinylated C-reactive protein. Immunology (2006) 1.16
Assembly and regulation of the membrane attack complex based on structures of C5b6 and sC5b9. Cell Rep (2012) 1.16
Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors. J Virol (2005) 1.15
Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein. J Virol (2003) 1.15
Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J Biol Chem (2011) 1.15
CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells. J Biol Chem (2005) 1.15
Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities. Mol Neurobiol (2002) 1.14
Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain (2010) 1.14
C-reactive protein and cardiovascular disease: weighing the evidence. Curr Atheroscler Rep (2006) 1.13
Complement component c1q mediates mitochondria-driven oxidative stress in neonatal hypoxic-ischemic brain injury. J Neurosci (2010) 1.13
Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proc Natl Acad Sci U S A (2011) 1.12
Complement abnormalities in acquired lipodystrophy revisited. J Clin Endocrinol Metab (2008) 1.10
A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood (2011) 1.09
Unique structure of iC3b resolved at a resolution of 24 Å by 3D-electron microscopy. Proc Natl Acad Sci U S A (2011) 1.09
Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int (2012) 1.09
Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer Res (2007) 1.09